• Issue

    Hepatology: Volume 54, Issue 5

    1493-1895
    November 2011
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

Obituary

Free Access

In Memoriam: Emmet B. Keeffe, M.D.†‡

Aijaz Ahmed M.D.,  Carlos O. Esquivel M.D., Ph.D., 
  • Pages: 1493-1495
  • First Published: 19 September 2011

Editorials

Free Access

Pentoxifylline for steatohepatitis: Magic bullet or smoking gun?†‡

Richard K. Sterling M.D., M.Sc.,  Arun J. Sanyal M.B.B.S., M.D., 
  • Pages: 1496-1499
  • First Published: 16 August 2011
Free Access

Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development†‡

Anna Alisi Ph.D.,  Rita Carsetti M.D.,  Valerio Nobili M.D., 
  • Pages: 1500-1502
  • First Published: 16 August 2011
Free Access

Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?†

Kathleen E. Corey M.D., M.P.H.,  Naga Chalasani M.D., F.A.C.G., 
  • Pages: 1503-1505
  • First Published: 27 September 2011

Viral Hepatitis

Free Access

The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A †‡

Karla J. Helbig,  Nicholas S. Eyre,  Evelyn Yip,  Sumudu Narayana,  Kui Li,  Guillaume Fiches,  Erin M. McCartney,  Rohit K. Jangra,  Stanley M. Lemon,  Michael R. Beard, 
  • Pages: 1506-1517
  • First Published: 11 July 2011
Free Access

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin†

Thomas-Matthias Scherzer,  Albert Friedrich Stättermayer,  Michael Strasser,  Hermann Laferl,  Andreas Maieron,  Rudolf Stauber,  Christian Datz,  Emina Dulic-Lakovic,  Petra Steindl-Munda,  Harald Hofer,  Peter Ferenci, 
  • Pages: 1518-1526
  • First Published: 11 July 2011
Free Access

Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial†‡

Marc G. Ghany,  Hae-Young Kim,  Anne Stoddard,  Elizabeth C. Wright,  Leonard B. Seeff,  Anna S.F. Lok,  the HALT-C Trial Group , 
  • Pages: 1527-1537
  • First Published: 11 July 2011
Free Access

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response†‡

Andrew J. Muir,  Fred F. Poordad,  John G. McHutchison,  Mitchell L. Shiffman,  Thomas Berg,  Peter Ferenci,  E. Jenny Heathcote,  Jean-Michel Pawlotsky,  Stefan Zeuzem,  Henk W. Reesink,  Geoffrey Dusheiko,  Emily C. Martin,  Shelley George,  Robert S. Kauffman,  Nathalie Adda, 
  • Pages: 1538-1546
  • First Published: 11 July 2011
Free Access

Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care†

Hamish A. Innes,  Sharon J. Hutchinson,  Samuel Allen,  Diptendu Bhattacharyya,  Peter Bramley,  Toby E.S. Delahooke,  John F. Dillon,  Ewan Forrest,  Andrew Fraser,  Ruth Gillespie,  David J. Goldberg,  Nicholas Kennedy,  Scott McDonald,  Allan McLeod,  Peter R. Mills,  Judith Morris,  Peter Hayes,  on behalf of the Hepatitis C Clinical Database Monitoring Committee. , 
  • Pages: 1547-1558
  • First Published: 11 July 2011

Free Access

Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C†‡

Lucy Golden-Mason,  Kiran M. Bambha,  Linling Cheng,  Charles D. Howell,  Milton W. Taylor,  Paul J. Clark,  Nezam Afdhal,  Hugo R. Rosen,  on behalf of the Virahep-C Study Group , 
  • Pages: 1559-1569
  • First Published: 11 July 2011
Free Access

Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytes†‡

Meital Gal-Tanamy,  Larisa Bachmetov,  Amiram Ravid,  Ruth Koren,  Arie Erman,  Ran Tur-Kaspa,  Romy Zemel, 
  • Pages: 1570-1579
  • First Published: 25 July 2011
Free Access

Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication†‡

Steve S. Choi,  Shelton Bradrick,  Guan Qiang,  Anahita Mostafavi,  Gaurav Chaturvedi,  Steven A. Weinman,  Anna Mae Diehl,  Ravi Jhaveri, 
  • Pages: 1580-1590
  • First Published: 25 July 2011
Free Access

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C†‡

Y.-F. Liaw,  J.-D. Jia,  H.L.Y. Chan,  K.H. Han,  T. Tanwandee,  W.L. Chuang,  D.M. Tan,  X.Y. Chen,  E. Gane,  T. Piratvisuth,  L. Chen,  Q. Xie,  J.J.Y. Sung,  C. Wat,  C. Bernaards,  Y. Cui,  P. Marcellin, 
  • Pages: 1591-1599
  • First Published: 11 July 2011

Steatohepatitis/Metabolic Liver Disease

Free Access

Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis†

Mary E. Rinella,  M. Shaddab Siddiqui,  Konstantina Gardikiotes,  Jeanne Gottstein,  Marc Elias,  Richard M. Green, 
  • Pages: 1600-1609
  • First Published: 11 July 2011
Free Access

Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial†‡§

Claudia O. Zein,  Lisa M. Yerian,  Prema Gogate,  Rocio Lopez,  John P. Kirwan,  Ariel E. Feldstein,  Arthur J. McCullough, 
  • Pages: 1610-1619
  • First Published: 11 July 2011
Free Access

Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice†‡

Liang Li,  Lei Chen,  Liang Hu,  Yuan Liu,  Han-Yong Sun,  Jing Tang,  Yu-Jie Hou,  Yan-Xin Chang,  Qian-Qian Tu,  Gen-Sheng Feng,  Feng Shen,  Meng-Chao Wu,  Hong-Yang Wang, 
  • Pages: 1620-1630
  • First Published: 11 July 2011

Steatohepatits/Metabolic Liver Disease

Free Access

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial†‡§

Dawn M. Torres,  Frances J. Jones,  Janet C. Shaw,  Christopher D. Williams,  John A. Ward,  Stephen A. Harrison, 
  • Pages: 1631-1639
  • First Published: 11 July 2011
Free Access

Urinary ethyl glucuronide as a novel screening tool in patients pre- and post–liver transplantation improves detection of alcohol consumption†‡§

Katharina Staufer,  Hilke Andresen,  Eik Vettorazzi,  Niels Tobias,  Bjoern Nashan,  Martina Sterneck, 
  • Pages: 1640-1649
  • First Published: 01 August 2011

Steatohepatitis/Metabolic Liver Disease

Open Access

Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance†‡§

Hui-Young Lee,  Andreas L. Birkenfeld,  Francois R. Jornayvaz,  Michael J. Jurczak,  Shoichi Kanda,  Violeta Popov,  David W. Frederick,  Dongyan Zhang,  Blas Guigni,  Kalyani G. Bharadwaj,  Cheol Soo Choi,  Ira J. Goldberg,  Jae-Hak Park,  Kitt F. Petersen,  Varman T. Samuel,  Gerald I. Shulman, 
  • Pages: 1650-1660
  • First Published: 25 July 2011

Hepatobiliary Malignancies

Free Access

Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans† ‡

Yeonghwan Kim,  Miran Jang,  Sangbin Lim,  Hyeran Won,  Kyung-Sik Yoon,  Jae-Hoon Park,  Hyo Jong Kim,  Byung-Ho Kim,  Won-Sang Park,  Joohun Ha,  Sung-Soo Kim, 
  • Pages: 1661-1678
  • First Published: 11 July 2011

Free Access

Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans†‡

Fu Yang,  Ling Zhang,  Xi-song Huo,  Ji-hang Yuan,  Dan Xu,  Sheng-xian Yuan,  Nan Zhu,  Wei-ping Zhou,  Guang-shun Yang,  Yu-zhao Wang,  Jing-li Shang,  Chun-fang Gao,  Feng-rui Zhang,  Fang Wang,  Shu-han Sun, 
  • Pages: 1679-1689
  • First Published: 18 July 2011
Free Access

Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: A study of hepatocellular carcinoma†

Tao Sun,  Bao-cun Sun,  Xiu-lan Zhao,  Nan Zhao,  Xue-yi Dong,  Na Che,  Zhi Yao,  Yue-mei Ma,  Qiang Gu,  Wen-kang Zong,  Zhi-yong Liu, 
  • Pages: 1690-1706
  • First Published: 11 July 2011
Free Access

Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis†‡

Haeryoung Kim,  Gi Hong Choi,  Deuk Chae Na,  Ei Young Ahn,  Gwang Il Kim,  Jae Eun Lee,  Jai Young Cho,  Jeong Eun Yoo,  Jin Sub Choi,  Young Nyun Park, 
  • Pages: 1707-1717
  • First Published: 11 July 2011
Free Access

The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis†‡

Fanyin Meng,  Yuyan Han,  Dustin Staloch,  Taylor Francis,  Allison Stokes,  Heather Francis, 
  • Pages: 1718-1728
  • First Published: 25 July 2011
Free Access

MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression†‡

Jian-Hong Fang,  Hui-Chao Zhou,  Chunxian Zeng,  Jine Yang,  Yinglin Liu,  Xiuzhi Huang,  Jing-Ping Zhang,  Xin-Yuan Guan,  Shi-Mei Zhuang, 
  • Pages: 1729-1740
  • First Published: 25 July 2011

Autoimmune, Cholestatic and Biliary Disease

Free Access

Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression†‡

Yoo-Mee Vanwijngaerden,  Joost Wauters,  Lies Langouche,  Sarah Vander Perre,  Christopher Liddle,  Sally Coulter,  Sara Vanderborght,  Tania Roskams,  Alexander Wilmer,  Greet Van den Berghe,  Dieter Mesotten, 
  • Pages: 1741-1752
  • First Published: 28 July 2011

Liver Injury/Regeneration

Free Access

Hepatotoxicity mediated by pyrazole (cytochrome P450 2E1) plus tumor necrosis factor alpha treatment occurs in c-Jun N-terminal kinase 2−/− but not in c-Jun N-terminal kinase 1−/− mice†‡

Xiaodong Wang,  Defeng Wu,  Lili Yang,  Arthur I. Cederbaum, 
  • Pages: 1753-1766
  • First Published: 11 July 2011
Free Access

Circulating microRNAs as potential markers of human drug-induced liver injury†‡§

Philip J. Starkey Lewis,  James Dear,  Vivien Platt,  Kenneth J. Simpson,  Darren G.N. Craig,  Daniel J. Antoine,  Neil S. French,  Neeraj Dhaun,  David J. Webb,  Eithne M. Costello,  John P. Neoptolemos,  Jonathan Moggs,  Chris E. Goldring,  B. Kevin Park, 
  • Pages: 1767-1776
  • First Published: 11 July 2011
Free Access

Endothelial nitric oxide synthase is a key mediator of hepatocyte proliferation in response to partial hepatectomy in mice†‡

Yu Mei,  Sundararajah Thevananther, 
  • Pages: 1777-1789
  • First Published: 11 July 2011

Liver Biology/Pathobiology

Free Access

Type 2 inositol 1,4,5-trisphosphate receptor modulates bile salt export pump activity in rat hepatocytes†‡

Emma A. Kruglov,  Samir Gautam,  Mateus T. Guerra,  Michael H. Nathanson, 
  • Pages: 1790-1799
  • First Published: 11 July 2011
Free Access

Conditional disruption of mouse HFE2 gene: Maintenance of systemic iron homeostasis requires hepatic but not skeletal muscle hemojuvelin†‡

Konstantinos Gkouvatsos,  John Wagner,  George Papanikolaou,  Giada Sebastiani,  Kostas Pantopoulos, 
  • Pages: 1800-1807
  • First Published: 11 July 2011
Free Access

Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis†‡

Ya-Li Jia,  Lei Shi,  Jun-Nian Zhou,  Chun-Jiang Fu,  Lin Chen,  Hong-Feng Yuan,  Yun-Fang Wang,  Xin-Long Yan,  Ying-Chen Xu,  Quan Zeng,  Wen Yue,  Xue-Tao Pei, 
  • Pages: 1808-1818
  • First Published: 11 July 2011

Liver Injury/Regeneration

Free Access

Hepatocytes internalize trophic receptors at large endocytic “Hot Spots”†‡

Hong Cao,  Eugene W. Krueger,  Mark A. McNiven, 
  • Pages: 1819-1829
  • First Published: 25 July 2011
Free Access

Identification and expansion of a unique stem cell population from adult mouse gallbladder†‡§

Rohan Manohar,  Junji Komori,  Lynda Guzik,  Donna B. Stolz,  Uma R. Chandran,  William A. LaFramboise,  Eric Lagasse, 
  • Pages: 1830-1841
  • First Published: 25 July 2011

Reviews

Free Access

Cancer surveillance in patients with primary sclerosing cholangitis†‡

Nataliya Razumilava,  Gregory J. Gores,  Keith D. Lindor, 
  • Pages: 1842-1852
  • First Published: 25 July 2011
Free Access

Ductular reactions in human liver: Diversity at the interface†‡

Annette S. H. Gouw,  Andrew D. Clouston,  Neil D. Theise, 
  • Pages: 1853-1863
  • First Published: 16 August 2011
Free Access

Intensive care of the patient with cirrhosis†

Jody C. Olson,  Julia A. Wendon,  David J. Kramer,  Vicente Arroyo,  Rajiv Jalan,  Guadalupe Garcia-Tsao,  Patrick S. Kamath, 
  • Pages: 1864-1872
  • First Published: 24 August 2011

Hepatology Elsewhere

Free Access

Opening the door for hepatitis C virus infection in genetically humanized mice†

Mirjam B. Zeisel Ph.D., PharmD,  Daniel Da Costa,  Thomas F. Baumert M.D., 
  • Pages: 1873-1875
  • First Published: 28 October 2011
Free Access

The long and the short of interferon-gamma–inducible protein 10 in hepatitis C virus infection†

Mark D. Gorrell Ph.D.,  Amany Zekry M.D., Ph.D., FRACP,  Geoffrey W. McCaughan M.D., Ph.D., FRACP,  Andrew Lloyd M.D., Ph.D., FRACP, 
  • Pages: 1875-1879
  • First Published: 28 October 2011
Free Access

Exhausted or just sleeping: Awakening virus-specific responses in chronic hepatitis C virus infection†

Nicole A.W. Wood B.Sc.,  May La Linn M.B.B.S., Ph.D.,  David G. Bowen M.B.B.S., Ph.D., 
  • Pages: 1879-1882
  • First Published: 28 October 2011
Free Access

Boceprevir (Victrelis) for HCV: V is for victory and very complex†

Michael Charlton M.D.,  Michael D. Leise M.D., 
  • Pages: 1882-1886
  • First Published: 28 October 2011

Image of the Month

Free Access

Liver infarction after transjugular intrahepatic portosystemic shunt in a liver transplant recipient†

Meng Y. Wang M.D.,  Darryn R. Potosky M.D.,  Sandeep Khurana M.B.B.S., 
  • Pages: 1887-1888
  • First Published: 19 September 2011

Correspondence

Free Access

Commentary on emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferon therapy†

Seyed Mohamad Jazayeri M.D., Ph.D.,  Seyed Moayed Alavian M.D., 
  • Page: 1889
  • First Published: 02 September 2011
Free Access

Reply:†

Chao-Wei Hsu M.D.,  Chau-Ting Yeh M.D., Ph.D., 
  • Pages: 1889-1890
  • First Published: 04 October 2011
Free Access

Targeting angiogenesis in chronic liver diseases with portal hypertension: anti–placenta growth factor inhibitor or multikinase inhibitor sorafenib?†

Romain Coriat M.D., M.Sc.,  Olivier Mir M.D., M.Sc.,  François Goldwasser M.D., Ph.D.,  Stanislas Pol M.D., Ph.D.,  Stanislas Chaussade M.D., Ph.D., 
  • Pages: 1890-1891
  • First Published: 19 September 2011
Free Access

Reply:†

Isabelle Colle M.D., Ph.D.,  Christophe Van Steenkiste M.D., Ph.D., 
  • Page: 1891
  • First Published: 10 October 2011
Free Access

Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomes†

Diarmaid D. Houlihan MBChB, BSc, MRCP,  Laurence J. Hopkins BSc,  Shankar X. Suresh BSc, MSc, MRes,  Matthew J. Armstrong MBChB, BSc, MRCP,  Philip N. Newsome PhD, MBChB, FRCPE, 
  • Pages: 1891-1892
  • First Published: 10 October 2011
Free Access

Reply:†

Liang Peng,  Zhi-liang Gao M.D., Ph.D., 
  • Page: 1892
  • First Published: 10 October 2011
Free Access

Seven cases of autoimmune hepatitis that developed after drug-induced liver injury†

Kazushi Sugimoto M.D., Ph.D.,  Takeshi Ito M.D., Ph.D.,  Norihiko Yamamoto M.D., Ph.D.,  Katsuya Shiraki M.D., Ph.D., 
  • Pages: 1892-1893
  • First Published: 02 July 2011
Free Access

Polynesian ecology determines seasonality of biliary atresia†

Muriel Girard M.D.,  Anne-Sophie Jannot Ph.D.,  MArianne Besnard M.D.,  Anne-Louise Leutenegger Ph.D.,  Emmanuel Jacquemin M.D., Ph.D.,  Stanislas Lyonnet M.D., Ph.D.,  Alexandra Henrion-Caude Ph.D., 
  • Pages: 1893-1894
  • First Published: 11 July 2011
Free Access

Cell line misidentification: The case of the Chang liver cell line†

Qiang Gao M.D., Ph.D.,  Xiao-Ying Wang M.D., Ph.D.,  Jian Zhou M.D., Ph.D.,  Jia Fan M.D., Ph.D., 
  • Pages: 1894-1895
  • First Published: 07 June 2011